DNA Dividend: Ginkgo Bioworks Holdings Inc Yield Insights

Income

Balance sheet

Cash flow

Annual

Quarterly

DNA Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	180	227	251	477	313	76
Revenue Growth (YoY)	-17%	-10%	-47%	52%	312%	41%
Cost of Revenue	49	44	54	204	129	15
Gross Profit	131	182	197	273	184	61
Selling, General & Admin	200	241	192	1,383	863	38
Research & Development	270	424	580	1,052	1,149	159
Operating Expenses	470	665	773	2,436	2,012	198
Other Non Operating Income (Expenses)	10	28	14	132	80	16
Pretax Income	-340	-547	-892	-2,121	-1,838	-124
Income Tax Expense	0	0	0	-15	-1	1
Net Income	-339	-547	-892	-2,104	-1,830	-126
Net Income Growth	-48%	-39%	-57.99%	15%	1,352%	6%
Shares Outstanding (Diluted)	55.63	51.89	48.61	1,679.1	1,359.8	1,874.8
Shares Change (YoY)	7%	7%	-97%	23%	-27%	0%
EPS (Diluted)	-6.1	-10.54	-18.36	-1.25	-1.35	-0.07
EPS Growth	-51%	-43%	1,369%	-7%	1,829%	17%
Free Cash Flow	-187	-382	-336	-304	-310	-193
Free Cash Flow Per Share	-3.36	-7.36	-6.91	-0.18	-0.22	-0.1
Gross Margin	72.77%	80.17%	78.48%	57.23%	58.78%	80.26%
Operating Margin	-188.33%	-212.77%	-229.48%	-453.24%	-584.02%	-180.26%
Profit Margin	-188.33%	-240.96%	-355.37%	-441.09%	-584.66%	-165.78%
Free Cash Flow Margin	-103.88%	-168.28%	-133.86%	-63.73%	-99.04%	-253.94%
EBITDA	-279	-420	-506	-2,120	-1,799	-124
EBITDA Margin	-155%	-185.02%	-201.59%	-444.44%	-574.76%	-163.15%
D&A For EBITDA	60	63	70	42	29	13
EBIT	-339	-483	-576	-2,162	-1,828	-137
EBIT Margin	-188.33%	-212.77%	-229.48%	-453.24%	-584.02%	-180.26%
Effective Tax Rate	0%	0%	0%	0.7%	0.05%	-0.8%